Atlas Capital Advisors Inc. Acquires New Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 500 shares of the company’s stock, valued at approximately $31,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of TransMedics Group in the fourth quarter valued at approximately $22,861,000. Emerald Advisers LLC lifted its holdings in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock worth $23,176,000 after buying an additional 220,804 shares during the period. Principal Financial Group Inc. increased its stake in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after buying an additional 146,115 shares during the period. State of Michigan Retirement System bought a new stake in shares of TransMedics Group in the fourth quarter valued at about $6,734,000. Finally, Raymond James Financial Inc. purchased a new stake in TransMedics Group in the fourth quarter worth about $3,845,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, March 26th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Piper Sandler cut their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Finally, Robert W. Baird decreased their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $67.67 on Friday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market cap of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. The business has a 50-day simple moving average of $70.07 and a two-hundred day simple moving average of $85.25.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.